Biomedicine & Pharmacotherapy · 2024 · 13 citations · 25 references
Life SciencesOncologyPharmacologyApoptosisAutophagyMolecular OncologyApoptosis In CancerApoptosis ModulationApoptosis RegulationAutophagy In CancerAutophagy ModulationAutophagy RegulationApoptosis Signaling In CancerAutophagy Modulation As TherapyCancer-associated AutophagyEndoplasmic Reticulum FunctionEukaryotic Initiation Factor 2Perk Signaling PathwaySmall Cell Lung Cancer TreatmentTherapeutic Plant Efficacy
Chinese herbs have been used to treat small-cell lung cancer (SCLC) due to their low toxicity and significant efficacy. This study focused on oridonin, a natural compound extracted from Rabdosia rubescens, and aimed to investigate its potential antitumor activity on SCLC and to evaluate the synergistic effect of combining oridonin with other small molecules. In this study, oridonin exhibited a dual effect. At lower concentrations, it suppressed the cell viability of SCLC cells (H1688 and H446). At high concentrations, oridonin induced SCLC cell apoptosis, damaged HBE cells in vitro and compromised the function of the liver and heart in vivo . The lower concentration of oridonin induced autophagy by enhancing the expression of p62 and the LC3B-II/LC3B-I ratio. This phenomenon might be associated with the activation of the protein kinase RNA-like ER kinase (PERK)/eukaryotic initiation factor 2 alpha (eIF2α)/growth arrest and DNA damage-inducible gene 153 (CHOP/GAD153) pathway. Therefore, the combined effect of oridonin with GSK2606414 or 3- methyladenine increased apoptosis in SCLC cells and reduced tumor growth. A similar phenomenon was observed after oridonin was combined with p62 or CHOP RNA interference treatment. Simultaneously, the combination of oridonin and GSK2606414 exhibited therapeutic efficacy without manifesting adverse effects. Our findings suggest that oridonin at lower concentrations can induce autophagy by activating the PERK/eIF2α/CHOP signaling pathway. The inhibition of the PERK/eIF2α/CHOP pathway could enhance oridonin therapeutic responses by triggering apoptosis. The novel therapeutic approach of combining oridonin with a PERK inhibitor is promising as a strategy for the treatment of SCLC. • Oridonin exhibited a dual effect in two type of small cell lung cancer cells, including H1688 and H466. • We validate that oridonin at lower concentration could trigger autophagy. • RNA sequence analysis revealed that endoplasmic reticulum (ER) stress is involved in Oridonin-induced autophagy. • The inhibition of the PERK/eIF2α pathway could enhance oridonin therapeutic responses by trigging apoptosis in small cell lung cancer.
25
Kasper M.A. Rouschop, Twan van den Beucken, Ludwig J. Dubois et al. · Journal of Clinical Investigation · 2009 · 802 citations · Full text
Evelyn M. Nguyen, Hirokazu Taniguchi, Joseph M. Chan et al. · Journal of Thoracic Oncology · 2022 · 131 citations · Full text